Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Longqi Capsule** is an orally administered traditional Chinese medicine candidate being developed for advanced non-small cell lung cancer, including patients characterized in traditional Chinese medicine terminology as having phlegm and blood stasis obstructing the lungs syndrome. It has been studied in randomized, double-blind, placebo-controlled clinical trials, including an earlier study in which both study arms received spirulina capsules as background treatment. No molecularly defined active constituent, direct biological target, or validated target-specific mechanism has been publicly established for the NSCLC product. The program has been associated with Jiangsu Kanion Pharmaceutical and earlier clinical development sponsors in Nanjing. ([synapse.patsnap.com](https://synapse.patsnap.com/drug/e105b8d809194b9095c0303c2be31273))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Longqi Capsule.